Phase 3 Safety and Imaging Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing Coronary Angiography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00156845|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : July 14, 2006
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Procedure: AI-700 contrast-enhanced echocardiography||Phase 3|
Assessment of myocardial perfusion has been demonstrated to provide both diagnostic and prognostic value to patients with ischemic heart disease by allowing the clinician to assess the hemodynamic significance of coronary artery disease (CAD). The primary objective of the clinical development program for AI-700 is to demonstrate the safety and efficacy of AI-700 as an intravenous ultrasound contrast agent in patients with suspected myocardial perfusion defects.
The patient population is comprised of patients being evaluated for inducible ischemia and indicated for coronary angiography. The primary study objective was to determine the accuracy, sensitivity, and specificity of AI-700-enhanced echocardiographic imaging for detecting CAD, using coronary angiography/left ventriculography (ANGIO/LVG) as the reference standard.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||450 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 3, International, Multicenter, Open-Label, Dual-Injection, Echocardiographic Imaging and Safety Study in Patients With Suspected Ischemic Heart Disease Undergoing Diagnostic Coronary Angiography (Real-Time Assessment of Myocardial Perfusion With Echocardiography: RAMP 2)|
|Study Start Date :||December 2003|
|Estimated Study Completion Date :||June 2006|
- Accuracy, sensitivity, and specificity of AI-700 ECHO in assessing CAD
- Safety of AI-700 administered IV to suspected CAD patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00156845
|United States, Massachusetts|
|Watertown, Massachusetts, United States, 02472|